Literature DB >> 18006700

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.

Mihály Józsi1, Christoph Licht, Stefanie Strobel, Svante L H Zipfel, Heiko Richter, Stefan Heinen, Peter F Zipfel, Christine Skerka.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a severe renal disease that is associated with defective complement regulation caused by multiple factors. We previously described the deficiency of factor H-related proteins CFHR1 and CFHR3 as predisposing factor for aHUS. Here we identify in an extended cohort of 147 aHUS patients that 16 juvenile individuals (ie, 11%) who either lacked the CFHR1/CFHR3 completely (n = 14) or showed extremely low CFHR1/CFHR3 plasma levels (n = 2) are positive for factor H (CFH) autoantibodies. The binding epitopes of all 16 analyzed autoantibodies were localized to the C-terminal recognition region of factor H, which represents a hot spot for aHUS mutations. Thus we define a novel subgroup of aHUS, termed DEAP HUS (deficiency of CFHR proteins and CFH autoantibody positive) that is characterized by a combination of genetic and acquired factors. Screening for both factors is obviously relevant for HUS patients as reduction of CFH autoantibody levels represents a therapeutic option.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006700     DOI: 10.1182/blood-2007-09-109876

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  130 in total

Review 1.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

2.  aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.

Authors:  Ekaterini Siomou; Athanasios Gkoutsias; Anastasios Serbis; Konstantinos Kollios; Nikolaos Chaliasos; Veronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-11-16       Impact factor: 3.714

3.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

4.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

Review 5.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

Review 6.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 7.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

9.  Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Authors:  Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

10.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.